PetroChina approves new northeast refinery complex, sources say
The new complex comprises a 200,000-barrel per day crude oil refinery, a 1.4 million metric ton per year ethylene complex as well as a variety of downstream petrochemical units such as polyethylene, polypropylene and polyolefin elastomer, said the official and one of the industry sources.
The official declined to be named because the decision is not yet public while the sources with knowledge of the matter spoke on condition of anonymity because they are not authorised to speak about it publicly.
It remains unclear when exactly the final investment decision for the new site was made.
The complex, to be built on Changxing Island, about two hours' drive from downtown Dalian, has an estimated cost of 68.5 billion yuan ($9.56 billion), said a second source.
The company did not immediately respond to a Reuters request for comment.
PetroChina has begun building some infrastructure at the site such as a jetty and pipelines, said one of the two industry sources.
Reuters has reported PetroChina was on track to close the whole 410,000-bpd refinery in downtown Dalian operated by subsidiary Dalian Petrochemical Corp, switching off the last crude oil unit last month and set to clean out refined fuel inventories by the end of August.
The mothballing of the old plant, PetroChina's largest domestic refinery in China, came amid refiners' struggle with overcapacity and weakened fuel demand from slowing economic growth and the electrification of the country's car fleet.
($1 = 7.1673 Chinese yuan renminbi)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
23 minutes ago
- Reuters
Regeneron beats second-quarter results estimates on Dupixent sales boost
Aug 1 (Reuters) - Regeneron Pharmaceuticals (REGN.O), opens new tab beat Wall Street estimates for second-quarter revenue and profit on Friday helped by robust demand for its blockbuster eczema treatment, Dupixent, sending its shares up nearly 3% in premarket trading. Investors have set a high bar for Regeneron and French partner Sanofi's ( opens new tab Dupixent, one of the U.S. drugmaker's growth drivers, especially after it received approval to treat a common lung condition called chronic obstructive pulmonary disease last year. Sales of the anti-inflammatory drug rose 22% to $4.34 billion, compared with an estimate of $4.14 billion. The Tarrytown, New York-based company is also banking its cancer treatment, Libtayo, to drive future growth at a time when its blockbuster eye disease drug Eylea has been grappling with stiff competition from cheaper versions and rival drugs such as Roche's (ROG.S), opens new tab Vabysmo. U.S. sales of Eylea, jointly developed with Bayer AG ( opens new tab, fell 25% to $1.15 billion, including $393 million from the higher, 8-milligram dose version of the drug. Analysts were expecting $2.17 billion in total Eylea sales. Roche reported Vabysmo sales of 2.07 billion Swiss francs ($2.54 billion) last week, slightly below analyst expectations. On an adjusted basis, Regeneron earned a quarterly profit of $12.89 per share, compared with analysts' average expectation of $8.44 per share, according to data compiled by LSEG. The company's total revenue for the quarter was $3.68 billion, above an expectation of $3.28 billion. Skin cancer drug Libtayo brought in sales of $377 million, versus analysts' average estimate of $338.75 million. Separately, Regeneron is among 17 drugmakers that have received a letter from the U.S. President Donald Trump asking them to slash U.S. prescription drug prices to match overseas rates. ($1 = 0.8161 Swiss francs)
Reuters
26 minutes ago
- Reuters
India's NSE settles with regulator for $4.6 million over data sharing case
Aug 1 (Reuters) - India's largest bourse operator, National Stock Exchange of India, has settled a matter involving the sharing of confidential information of listed companies indirectly to a third-party vendor with the markets regulator for 403.5 million rupees ($4.6 million), the regulator said on Friday. ($1 = 87.4580 Indian rupees)
Reuters
26 minutes ago
- Reuters
Canada's Imperial Oil posts fall in quarterly profit on lower crude prices
Aug 1 (Reuters) - Canadian oil producer Imperial Oil ( opens new tab posted a fall in second-quarter profit on Friday, hurt by lower crude prices and a decline in refinery throughput. Benchmark Brent crude prices were lower during the April-June quarter compared to a year earlier, pressured by weak global demand, market volatility due to tariffs and increased oil supply from OPEC+. The company's refinery throughput volumes fell to 376,000 barrels per day during the second quarter from 387,000 bpd a year ago. The Calgary, Alberta-based company said its net income fell to C$949 million ($684.31 million), or C$1.86 per share, in the quarter ended March 31, from C$1.13 billion, or C$2.11 per share, a year earlier. ($1 = 1.3868 Canadian dollars)
